A detailed history of Price T Rowe Associates Inc transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,114,885 shares of ORIC stock, worth $9.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,114,885
Previous 1,189,227 6.25%
Holding current value
$9.15 Million
Previous $8.41 Million 35.91%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.52 - $11.9 $559,051 - $884,669
-74,342 Reduced 6.25%
1,114,885 $11.4 Million
Q2 2024

Aug 14, 2024

SELL
$6.63 - $12.93 $2.5 Million - $4.88 Million
-377,509 Reduced 24.1%
1,189,227 $8.41 Million
Q1 2024

May 15, 2024

BUY
$8.04 - $16.03 $7.36 Million - $14.7 Million
915,175 Added 140.46%
1,566,736 $21.5 Million
Q4 2023

Feb 14, 2024

BUY
$5.41 - $9.43 $3.28 Million - $5.72 Million
606,446 Added 1344.22%
651,561 $6 Million
Q3 2023

Nov 14, 2023

SELL
$6.05 - $9.28 $108,591 - $166,566
-17,949 Reduced 28.46%
45,115 $274,000
Q2 2023

Aug 14, 2023

BUY
$4.95 - $8.4 $18,438 - $31,290
3,725 Added 6.28%
63,064 $490,000
Q3 2022

Nov 14, 2022

BUY
$3.15 - $5.24 $21,735 - $36,156
6,900 Added 13.16%
59,339 $191,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.07 $30,296 - $79,332
-11,221 Reduced 17.63%
52,439 $235,000
Q1 2022

May 16, 2022

BUY
$4.54 - $16.1 $72,145 - $255,845
15,891 Added 33.27%
63,660 $340,000
Q4 2021

Feb 14, 2022

BUY
$12.01 - $20.3 $573,705 - $969,710
47,769 New
47,769 $702,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $325M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.